Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors

Biochimie

Volumn 108, Issue , 2015, Pages 101-107

  Vázquez, Ramiro ^a,b   Astorgues Xerri, Lucile ^a,c   Bekradda, Mohamed ^a   Gormley, Julie ^d   Buick, Richard ^d   Kerr, Paul ^d   Cvitkovic, Esteban ^a   Raymond, Eric ^c   D'Incalci, Maurizio ^b   Frapolli, Roberta ^b   Riveiro, María E ^a  

^a Oncology Therapeutic Development   (France)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c BEAUJON HOSPITAL   (France)

^d FUSION ANTIBODIES LTD   (United Kingdom)

Author keywords

Cathepsin S; Cathepsin S blockade; Cell invasiveness; Colo 205 xenografts; Fsn0503h antibody

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN S; FSN 0503H ANTIBODY; PEPTIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; CATHEPSIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL INVASION; COLON CARCINOMA; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZATION; SOLID TUMOR; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

CITRUS MACROPHYLLA;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CATHEPSINS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM INVASIVENESS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84913584433     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2014.10.025     Document Type: Article

References (41)

1. S. Gupta, R.K. Singh, S. Dastidar, and A. Ray Cysteine cathepsin S as an immunomodulatory target: present and future trends Expert. Opin. Ther. Targets 12 3 2008 291 299
2. M.M. Mohamed, and B.F. Sloane Cysteine cathepsins: multifunctional enzymes in cancer Nat. Rev. Cancer 6 10 2006 764 775
3. D.M. Small, R.R. Burden, and C.J. Scott The emerging relevance of the cysteine protease cathepsin S in disease Clin. Rev. Bone Min. Metab. 9 2011 122 132
4. J. Dennemärker, T. Lohmüller, J. Mayerle, M. Tacke, M.M. Lerch, L.M. Coussens, C. Peters, and T. Reinheckel Deficiency for cysteine protease cathepsin L promotes tumor progression in mouse epidermis Oncogene 29 11 2010 1611 1621
5. F. Qian, S.J. Chan, Q.M. Gong, A.S. Bajkowski, D.F. Steiner, and A. Frankfater The expression of cathepsin B and other lysosomal proteinases in normal tissues and in tumors Biomed. Biochim. Acta 50 4-6 1991 531 540
6. G.P. Shi, J.S. Munger, J.P. Meara, D.H. Rich, and H.A. Chapman Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease J. Biol. Chem. 267 11 1992 7258 7262
7. R.J. Riese, R.N. Mitchell, J.A. Villadangos, G.P. Shi, J.T. Palmer, E.R. Karp, G.T. De Sanctis, H.L. Ploegh, and H.A. Chapman Cathepsin S activity regulates antigen presentation and immunity J. Clin. Invest 101 11 1998 2351 2363
8. G.P. Shi, J.A. Villadangos, G. Dranoff, C. Small, L. Gu, K.J. Haley, R. Riese, H.L. Ploegh, and H.A. Chapman Cathepsin S required for normal MHC calss II peptide loading and germinal cancer development Immunity 10 2 1999 197 206
9. N. Naour, C. Rouault, S. Fellahi, M.E. Lavoie, C. Poitou, M. Keophiphath, D. Eberlé, S. Shoelson, S. Rizkalla, J.P. Bastard, R. Rabasa-Lhoret, K. Clément, and M. Guerre-Millo Cathepsins in human obesity: changes in energy balance predominantly affect cathepsin S in adipose tissue and in circulation J. Clin. Endocrinol. Metab. 95 4 2010 1861 1868
10. S. Taleb, D. Lacasa, J.P. Bastard, C. Poitou, R. Cancello, V. Pelloux, N. Viquerie, A. Venis, J.D. Zucker, J.L. Bouillot, C. Coussieu, A. Basdevant, D. Langin, and K. Clement Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis FASEB J. 19 1 2005 1540 1542
11. C.A. Lemere, J.S. Munger, G.P. Shi, L. Natkin, C. Haass, H.A. Chapman, and D.J. Selkoe The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and down syndrome brain. An immunocytochemical study Am. J. Pathol. 146 4 1995 848 860
12. I. Schechter, and E. Ziv Cathepsins S, B and L with aminopeptidases display β-secretase activity associated with pathogenesis of Alzhaimer's disease Biol. Chem. 392 6 2011 555 569
13. O. Vasiljeva, T. Reinheckel, C. Peters, D. Turk, and B. Turk Emerging roles of cysteine cethepsins in disease and their potential as drug targets Curr. Pharm. Des. 13 4 2007 387 403
14. V.Y. Reddy, Q.Y. Zhang, and S.J. Weiss Pericellular mobilization of tissue destructive cysteine proteinases, cathepsins B, L and S, by human monocyte derived macrophages Proc. Natl. Acad. Sci. U. S. A. 92 1995 3849 3853
15. E. Jobs, U. Risérus, E. Ingelsson, J. Sundström, M. Jobs, E. Nerpin, D. Iggman, S. Basu, A. Larsson, L. Lind, and J. Ärnlöv Serum cathepsin S is associated with decreased insulin sensitivity and the development of type 2 diabetes in a community-based cohort of elderly men Diabetes Care 36 1 2013 163 165
16. H.R. Seo, S. Bae, and Y.S. Lee Radiation-induced cathepsin S is involved in radioresistance Int. J. Cancer 124 8 2009 1794 1801
17. J.A. Gormley, S.M. Hegarty, A. O'Grady, M.R. Stevenson, R.E. Burden, H.L. Barrett, C.J. Scott, J.A. Johnston, R.H. Wilson, E.W. Kay, P.G. Johnston, and S.A. Olwill The role of cathepsin S as marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study Br. J. Cancer 105 8 2011 1487 1494
18. J. Xu, D. Li, Z. Ke, R. Liu, G. Maubach, and L. Zhou Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma Mol. Med. Rep. 2 5 2009 713 718
19. Q. Fan, X. Wang, H. Zhang, C. Li, J. Fan, and J. Xu Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro Biochem. Biophys. Res. Commun. 425 4 2012 703 710
20. P.L. Fernandez, X. Farre, A. Nadal, E. Fernandez, N. Peiro, B. Sloane, G.-P. Shi, H. Chapman, E. Campo, and A. Cardesa Expression of cathepsins B and S in the progression of prostate carcinoma Int. J. Cancer 95 1 2001 51 55
21. T. Flannery, D. Gibson, M. Mirakhur, S. McQuaid, C. Greenan, A. Trimble, B. Walker, D. McCormick, and P.G. Johnston The clinical significance of cathepsin S expression in human astrocytomas Am. J. Pathol. 163 1 2003 175 182
22. T. Flannery, S. McQuaid, C. McGoohan, R.S. McConnell, G. McGregor, M. Mirakhur, P. Hamilton, J. Diamond, G. Cran, B. Walker, C. Scott, L. Martin, D. Ellison, C. Patel, C. Nicholson, D. Mendelow, D. MacCormick, and P.G. Johnston Cathepsin S expression in glioblastomatumours - a pilot study Int. J. Cancer 119 4 2006 854 860
23. C. Jedeszko, and B.F. Sloane Cysteine cathepsins in human cancer Biol. Chem. 385 11 2004 1017 1027
24. B. Wang, J. Sun, S. Kitamoto, M. Yang, A. Grubb, H.A. Chapman, R. Kalluri, and G.P. Shi Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors J. Biol. Chem. 281 9 2006 6020 6029
25. D.M. Small, R.E. Burden, J. Jaworski, S.M. Hegarty, S. Spence, J.F. Burrows, C. McFarlane, A. Kissenpfennig, H.O. McCarthy, J.A. Johnston, B. Walker, and C.J. Scott Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization Int. J. Cancer 133 9 2013 2102 2112
26. R.E. Burden, J.A. Gormley, T.J. Jaquin, D.M. Small, D.J. Quinn, S.M. Hegarty, C. Ward, B. Walker, J.A. Johnston, S.A. Olwill, and C.J. Scott Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis Clin. Cancer Res. 15 9 2009 6042 6051
27. C. Ward, D. Kuehn, R.E. Burden, J.A. Gormley, T.J. Jaquin, M. Gazdoiu, D. Samall, R. Bicknel, J.A. Jonhsnton, C.J. Scott, and S.A. Olwill Antibody targeting of cathepsin S inhibits angiogenesis synergistically enhaces anti-VEGF Plos One 5 9 2010 pii:e12543
28. R.E. Burden, J.A. Gormley, D. Kuehn, C. Ward, H.F. Kwok, M. Gazdoiu, A. McClurg, T.J. Jaquin, J.A. Johnston, C.J. Scott, and S.A. Olwill Inhibition of Cathepsin S by Fsn0503 enhaces the efficacy of chemotherapy in colorectal carcinomas Biochimie 94 2 2012 487 493
29. H.F. Kwok, R.J. Buick, D. Kuehn, J.A. Gormley, D. Doherty, T.J. Jaquin, A. McClurg, C. Ward, T. Byrne, J. Jaworski, K.L. Leung, O. Snoddy, C. McAnally, R.E. Burden, B. Gray, J. Lowry, I. Sermadiras, N. Gruszka, N. Courtenay-Luck, A. Kissenpfenning, C.J. Scott, and S.A. Olwill Antibody targeting of cathepsin S induces antibody-dependent cellular cytotoxicity Mol. Cancer 10 2011 147
30. M. Meissner, T.L. Whiteside, R. Kaufmann, and B. Seliger CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells Arch. Dermatol. Res. 301 2 2009 189 193
31. A. Fritah, C. Saucier, O. De Wever, M. Bracke, I. Bièche, R. Lidereau, C. Gespach, S. Drouot, G. Redeuilh, and M. Sabbah Role of WISP-2/CCn5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells Moll. Cell. Bio 28 3 2008 1114 1123
32. A. Ghoul, M. Serova, L. Astorgues-Xerri, K. Bièche, G. Bousquet, M. Varna, M. Vidaud, E. Phillips, S. Weill, K.A. Benhadji, F. Lokiec, E. Cvitkovic, S. Faivre, and E. Raymond Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells Cancer Res. 69 10 2009 4260 4269
33. B. De Craene, B. Gilbert, C. Stove, E. Bruyneel, F. van Roy, and G. Berx The transcription factor snail induces tumor cell invasion through modulation of the epithelial differentiation program Cancer Res. 65 14 2005 6237 6244
34. T. Shree, O.C. Olson, B.T. Elie, J.C. Kester, A.L. Garfall, K. Simpson, K.M. Bell-McGuinn, E.C. Zabor, E. Brogi, and J.A. Joyce Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer Genes. Dev. 25 23 2011 2465 2479
35. M. Serova, A. de Gramont, A. Tijeras-Raballand, C. Dos Santos, M.E. Riveiro, K. Slimane, S. Faivre, and E. Raymond Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal carcinoma models developing resistance to sunitinib and sorafenib Cancer Chemother. Pharmacol. 71 5 2013 1297 1307
36. C.M. Overall, and O. Kleifeld Tumour microenviroment - opinion: validating matrix metallopoteinases as drug targets and anti-targets for cancer therapy Nat. Rev. Cancer 6 3 2006 227 239
37. K.W. Ng Potential role of odanacatib in the treatment of osteosporosis Clin. Interv. Aging 7 2012 235 247
38. M. Taritahbrizi, G.G. Bornstein, and H. Suria Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease AAPS J. 12 1 2010 33 43
39. B. Walker, J.F. Lynas, M.A. Meighan, and D. Brömme Evaluation of dipeptide alpha-keto-beta-aldehydes as new inhibitors of cathepsin S Biochem. Biophys. Res. Commun. 275 2 2000 401 405
40. A. Lee-Dutra, D.K. Wiener, and S. Sun Cathepsin S inhibitors: 2004-2010 Expert. Opin. Ther. Pat. 21 3 2011 311 337
41. J.J. Wiener, S. Sun, and R.L. Thurmond Recent advances in the design of cathepsin S inhibitors Curr. Top. Med. Chem. 10 7 2010 717 732